Drugs / D013
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT05698043 | Jul → Sep 2023 | hyperlipidemia, combined, 2 | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT05552495 | Sep → Nov 2022 | hyperlipidemia, combined, 2 | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT05245084 | Mar → Jun 2022 | hyperlipidemia, combined, 2 | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT04987970 | Sep → Nov 2021 | — | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT04694989 | Feb → Apr 2021 | hyperlipidemia, combined, 2 | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT03920579 | Apr → May 2019 | hyperlipidemia, hypertensive disorder | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT03609606 | Aug → Sep 2018 | hyperlipidemia, hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04312698 | Aug 2019 → Jun 2021 | hyperlipidemia | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04388215 Comparator | Oct 2019 → Apr 2021 | essential hypertension, hyperlipidemia | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | D013 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04388215 ↗ |
| Route | Oral | “Daily oral administration of 1 tablet” NCT03609606 ↗ |